MedTrace Logo

Combination of Local Therapy and Target Therapy for Brain Metastases With EGFR Mutation

NCT05616377 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2022-11-15

No results posted yet for this study

Summary

The goal of this observational study is to learn about the survival benefit of local therapy combination with target therapy in lung cancer brain metastases with EGFR mutation. The main questions it aims to answer are:

* Is local therapy performed before or after target therapy would provide survival benefit ?
* What kind of local therapy combining with target therapy would provide survival benefit, neurosurgical resection or radiotherapy?

Conditions

Interventions

OTHER

Surgery or Radiotherapy

Participants who underwent target therapy and surgery or radiotherapy were divided into target therapy + local therapy group. Participants who underwent target therapy alone were divided into target therapy alone group

OTHER

before or after target therapy

Participants who underwent surgery or radiotherapy before target therapy were divided into local therapy before target therapy group. Participants who underwent surgery or radiotherapy after target therapy were divided into local therapy after target therapy group.

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-20
Primary Completion
2023-08-20
Completion
2024-11-20

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05616377 on ClinicalTrials.gov